ARHGEF17

Across TCGA pan-cancer cohorts, ARHGEF17 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGEF17 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARHGEF17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF17 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where ARHGEF17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.665	0.972	.001	31	view →
CCRCC	DFS	Quartile	III,IV	0.801	0.379	.006	14	view →
UCEC	OS	Tertile	II,III,IV	0.553	1.000	.014	8	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	7	view →
LSCC	DFS	Tertile	II,III,IV	0.834	1.000	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGEF17–LUAD (DFS)

Open the LUAD breakdown →